NewAmsterdam Pharma (NAMS) Research & Development (2023 - 2026)
NewAmsterdam Pharma's Research & Development was $41.67 million in Q2 2026, up 51.5% from $27.52 million a year earlier and up 9.6% from the prior quarter.
Powered by 
Analysis
NewAmsterdam Pharma (NAMS) Research & Development (2023 - 2026) Analysis & Trends
On a trailing twelve-month basis, NewAmsterdam Pharma's Research & Development was $149.25 million through Jun 30, 2026, up 4.5% year-over-year; for FY2025, it was $141.83 million, down 6.3% from FY2024.
- Research & Development shows a five-year compound annual growth rate of 98.4% (FY2020 to FY2025).
- In earlier years, Research & Development was $151.41 million in FY2024 (-5.0%), $159.42 million in FY2023 (+83.8%), $86.74 million in FY2022 (+199.4%) and $28.97 million in FY2021 (+527.3%).
- The Q2 2026 figure marks the highest quarterly Research & Development since Q1 2025.
- Compared with a year earlier, Research & Development was higher in three of the last eight quarters, with an average decline of 2.8%.
- The best year-over-year quarter for Research & Development over five years was Q2 2026 (growth of 51.5%); the worst was Q2 2025 (a decline of 28.3%).
- Per Business Quant data, NAMS's Research & Development in the three quarters before Q2 2026 was $38.01 million (Q1 2026), $38.59 million (Q4 2025) and $30.97 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,138.83 Bn | 1,107.41 Bn | 19.71 Bn | 3.82 Bn |
| 2 | Johnson & Johnson | 618.88 Bn | 537.41 Bn | 17.26 Bn | 3.65 Bn |
| 3 | AbbVie | 502.93 Bn | 476.04 Bn | 12.70 Bn | 2.34 Bn |
| 4 | Merck | 369.61 Bn | 323.99 Bn | 12.21 Bn | 9.74 Bn |
| 5 | Novartis Ag | 298.70 Bn | 262.69 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 261.35 Bn | 235.03 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 237.59 Bn | 192.99 Bn | 7.24 Bn | 1.87 Bn |
| 8 | Gilead Sciences | 191.60 Bn | 165.79 Bn | 6.22 Bn | 1.76 Bn |
| 9 | Pfizer | 170.23 Bn | 116.88 Bn | 10.94 Bn | 2.81 Bn |
| 10 | NewAmsterdam Pharma | 2.66 Bn | 49.48 Mn | - | 41.67 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 41.67 Mn |
| Mar 31, 2026 | 38.01 Mn |
| Dec 31, 2025 | 38.59 Mn |
| Sep 30, 2025 | 30.97 Mn |
| Jun 30, 2025 | 27.52 Mn |
| Mar 31, 2025 | 44.75 Mn |
| Dec 31, 2024 | 34.90 Mn |
| Sep 30, 2024 | 35.70 Mn |
| Jun 30, 2024 | 38.38 Mn |
| Mar 31, 2024 | 42.43 Mn |
| Dec 31, 2023 | 41.29 Mn |
| Sep 30, 2023 | 43.37 Mn |
| Jun 30, 2023 | 34.34 Mn |
| Mar 31, 2023 | 40.42 Mn |
API Access
NewAmsterdam Pharma Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=NAMS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "NAMS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=NAMS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();